1. Mechanism of Action:
- Semaglutide: A GLP-1 receptor agonist that mimics the natural hormone GLP-1, helping to regulate appetite and reduce calorie intake, leading to effective weight loss.
- Tirzepatide: A dual GIP and GLP-1 receptor agonist, acting on both receptors to enhance weight management, often leading to greater weight loss compared to GLP-1 agonists alone.
2. Weight Loss Efficacy:
- Semaglutide: Studies show a 15-18% reduction in baseline body weight over 68 weeks at a 2.4 mg dose.
- Tirzepatide: Clinical trials indicate weight loss of 15-21% depending on dosage (5 mg, 10 mg, 15 mg), with enhanced efficacy due to its dual action.
3. Side Effects:
- Common to Both: Nausea, diarrhea, vomiting, constipation, and abdominal pain, mostly related to gastrointestinal effects.
- Semaglutide: Headaches and fatigue are additional possible side effects.
- Tirzepatide: May cause increased heart rate and injection site reactions.
4. Contraindications:
- Semaglutide: Avoid in patients with a personal or family history of medullary thyroid carcinoma or MEN 2, and use cautiously in those with a history of pancreatitis.
- Tirzepatide: Similar contraindications as semaglutide, with additional considerations for patients with gastrointestinal disease or kidney problems.
Additional Weight Loss Medications:
- Phentermine: A well-known appetite suppressant that aids in short-term weight loss by reducing hunger. It's often prescribed for individuals needing quick weight reduction alongside lifestyle changes.
- Naltrexone/Bupropion (Contrave): A combination drug that targets the brain’s reward system to reduce cravings and manage hunger. It helps control eating behaviors in patients struggling with food addiction.
- NAD+: A coenzyme that supports metabolic function and energy production. NAD+ therapy is used to enhance fat metabolism, improve muscle recovery, and promote overall wellness, making it an effective complement to weight loss regimens.
Emerging Research Products:
- Retratrutide: A promising new medication currently under research. It's a triple-agonist targeting GLP-1, GIP, and glucagon receptors, potentially offering even more effective weight loss and metabolic benefits than current therapies like Tirzepatide.
Importance of a Comprehensive Approach: Working with Ruth Mash, ARNP, ensures personalized, well-monitored care, utilizing the most effective medications available. Each treatment is tailored to individual health profiles, providing the support needed to achieve long-term weight loss success.